cases of nodular hyperplasia and in tumour cells in most cases ofprostatic adenocarcinoma. Although CK7 (RCK105) was expressed by luminal epithelium in 57% of cases of nodular hyperplasia, it was not detected in any case of prostatic adenocarcinoma (figs 1 and 2). This difference remained statistically significant at the 5% level even after taking account of the large number of antibodies tested, by applying Vimentin and cytokeratin expression in nodular hyperplasia and prostate cancer Vimentin expression was more commonly detected in benign than malignant disease on frozen sections, confirming the observations of Leong et al. 9 The identification of this protein in an individual case is, therefore, not indicative of malignant disease of the prostate.
Sherwood et al'9 identified expression of CK5, 7, 8, 15, 18, 19 , and trace amounts of CK13 on immunoblot analysis of the luminal epithelium of normal prostates and cases of nodular hyperplasia. Predictably, therefore, in the present study, the antibodies which reacted most frequently in cases of nodular hyperplasia were those directed against one or more of these cytokeratins.
Chou et al6 have reported a difference in the percentage of cells reacting with anti-cytokeratin antibodies in adenocarcinoma and nodular hyperplasia. In the present study, however, most of the antibodies which reacted with the luminal epithelium in nodular hyperplasia and with tumour cells in cases of carcinoma did so in approximately equal proportions of cases (table 2) .
CK7 was not identified in any case of prostatic carcinoma, but was usually detected in In conclusion, vimentin expression does not distinguish between nodular hyperplasia and carcinoma of the prostate, as it occurs in both.
